Industry Information

Update June 30, 2021

Reveal the list! The fifth batch of centralized procurement results announced

Just now, Shanghai Sunshine Pharmaceutical Purchasing Network announced the results of the fifth batch of centralized procurement; 61 procurements were successful, with an average price reduction of...

Update June 29, 2021

List of drugs that are expected to be negotiated for medical insurance in 2021! Qilu, Hengrui, Rongchang Biological...

Since 2016, the country has negotiated drug prices every year, and 5 rounds of medical insurance negotiations have been conducted. The first round of medical insurance negotiations was led by the...

Update June 28, 2021

[Yao Kajun] 37 new drugs were approved for clinical use, from CP Tianqing, Hengrui, Kelun...

Highlights: 1. 37 new drugs obtained implied approval for clinical trials, including 24 domestically produced Class 1 new drugs 2. CDE newly accepted clinical trial applications for 19 new drugs (33...

Update June 26, 2021

The results of the fifth batch of national centralized purchasing are analyzed in 4 figures

The fifth batch of national procurement with volume (hereinafter referred to as "this national procurement") was carried out in Shanghai the day before yesterday, and the results of the proposed...

Update June 19, 2021

Loss of 700 million a year! It only took 5 years from the establishment to the IPO. Why is Heyu Biotech?

The latest news on June 17th, Shanghai Heyu Biomedical Technology Co., Ltd. submitted a prospectus to the Hong Kong Stock Exchange on the evening of June 16th, intending to list on the main board,...

Update June 18, 2021

There are nearly 50 dual antibodies under development in China, and Corning Jereh KN046 is expected to be listed in 2022; Kangfang Biology, Hengrui Medicine...

On June 7, Corning Jerry, the global leader in the development of PD-(L)1/CTLA-4 dual antibodies, announced PD-L1/CTLA-4 in the form of a poster at the 2021 American Society of Clinical Oncology...

Update June 17, 2021

About to break out! Contains a lot of unmet needs, the track that Hillhouse and Sequoia love super!

After the early collection of coronary stents and the upcoming blowout of orthopedic consumables, the market’s "favor and favor for devices" seems to have receded. Following the Hong Kong Stock...

Update June 16, 2021

Baike Biologics purchase day: there is no need to use the "nasal spray new crown vaccine", the shingles vaccine is the core growth point

A few days ago, at a press conference held by the Joint Prevention and Control Mechanism of the State Council, a reporter had just asked about the latest research status and characteristics of my...

Update June 15, 2021

The gene therapy market broke out! The market size will exceed 30.54 billion U.S. dollars in 2025

Since 2015, the global gene therapy industry has accelerated its development and continued to make breakthroughs. Especially after 2017, with the launch of the adeno-associated virus drug Luxturna...

Update June 11, 2021

First-line dual immunotherapy for pleural mesothelioma! Bristol-Myers Squibb's immune combination therapy approved in China

On June 10, according to the official website of the National Medical Products Administration (NMPA) of China, Bristol-Myers Squibb's immune combination therapy was approved for marketing in China...